Aurobindo Pharma Limited Stock Price Today (NSE: AUROPHARMA)
Fundamental Score
Aurobindo Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aurobindo Pharma Limited share price today is ₹1645.00, up +1.41% on NSE/BSE as of 24 August 2026. Aurobindo Pharma Limited (AUROPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹90.04K (Cr). The 52-week high for AUROPHARMA share price is ₹1682.40 and the 52-week low is ₹1016.10. At a P/E ratio of 24.25x, AUROPHARMA is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 9.94% and a debt-to-equity ratio of 0.20.
Aurobindo Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Aurobindo Pharma Limited share price chart: -0.70% return over the past month. 52-week high ₹1682.40, 52-week low ₹1016.10.
Aurobindo Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1631.00 | ₹1645.90 | ₹1626.30 | ₹1645.00 | 5.74L (Cr) | |
| ₹1662.40 | ₹1670.00 | ₹1621.90 | ₹1622.10 | 8.25L (Cr) | |
| ₹1666.00 | ₹1682.40 | ₹1654.50 | ₹1663.40 | 9.63L (Cr) | |
| ₹1658.00 | ₹1667.00 | ₹1652.30 | ₹1667.00 | 7.96L (Cr) | |
| ₹1648.00 | ₹1658.00 | ₹1639.90 | ₹1658.00 | 4.21L (Cr) | |
| ₹1668.00 | ₹1671.90 | ₹1635.20 | ₹1648.00 | 11.65L (Cr) | |
| ₹1580.10 | ₹1662.40 | ₹1579.90 | ₹1658.00 | 19.99L (Cr) | |
| ₹1625.00 | ₹1634.40 | ₹1584.20 | ₹1588.90 | 12.99L (Cr) | |
| ₹1587.30 | ₹1625.00 | ₹1567.00 | ₹1613.40 | 13.85L (Cr) | |
| ₹1555.00 | ₹1585.90 | ₹1536.80 | ₹1585.90 | 22.43L (Cr) |
Aurobindo Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1586.90 | ₹1682.40 | ₹1536.80 | ₹1645.00 | +3.66% | |
| ₹1578.70 | ₹1636.80 | ₹1512.00 | ₹1580.20 | +0.10% | |
| ₹1426.40 | ₹1588.90 | ₹1391.00 | ₹1578.70 | +10.68% | |
| ₹1398.00 | ₹1550.00 | ₹1367.00 | ₹1426.40 | +2.03% | |
| ₹1332.20 | ₹1459.50 | ₹1266.10 | ₹1389.50 | +4.30% | |
| ₹1186.20 | ₹1330.00 | ₹1179.80 | ₹1304.40 | +9.96% | |
| ₹1172.10 | ₹1250.90 | ₹1106.00 | ₹1220.40 | +4.12% | |
| ₹1190.00 | ₹1270.80 | ₹1116.20 | ₹1207.70 | +1.49% | |
| ₹1229.00 | ₹1240.70 | ₹1160.50 | ₹1183.00 | -3.74% | |
| ₹1142.90 | ₹1249.90 | ₹1120.00 | ₹1226.70 | +7.33% | |
| ₹1086.90 | ₹1155.80 | ₹1066.80 | ₹1138.90 | +4.78% | |
| ₹1022.80 | ₹1138.00 | ₹1016.10 | ₹1083.90 | +5.97% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Aurobindo's buyback is a band-aid on a generics business facing pricing pressure; look for pipeline catalysts, not financial engineering.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Aurobindo Pharma's board approved a share buyback on April 6, 2026, at , a 10% premium to the then-current market price. The buyback involves up to 54,23,728 shares, approximately 0.93% of the total paid-up equity. April 17, 2026, is the record date for determining shareholder eligibility.
CORE STORY (THE REAL GAME)
Shareholder value play. Aurobindo is using excess cash to boost EPS via buyback, signaling confidence despite generic pricing headwinds. This isn't about innovation, it's about financial engineering.
- ₹800 Cr buyback approved
- Q3 profit up 8% YoY
- Solar acquisition extended
- Successful ANDA filings in US
- New drug approvals in Europe
- Faster-than-expected integration of Zentiva acquisition (2025)
- Generics pricing pressure
- US regulatory risk
- High promoter pledging at 17.5%
DII increased stake by 0.67%, FII decreased by 0.17% — mixed signals.
Indian pharma exports are rising, but US tariff risks loom.
Yes — ₹4214.84 Cr Free Cash Flow 5Y.
Near-term: Buyback provides support. Mid-term: US generics pricing and pipeline execution are key.
Primary Thesis Risk
US generics pricing pressure will erode profitability despite buyback.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Aurobindo Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aurobindo Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AUROPHARMA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Operating Margins (19.65%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 24.25 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (25.20%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (16.30%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.20)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (14.31x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.81)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹5096.88 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 41.06%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
4 factors identified
Below-Average Return on Equity (9.94%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Weak Earnings Growth (-7.90% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-8.07% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
High Share Pledging Risk (23.65%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Aurobindo Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Aurobindo Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Aurobindo Pharma LimitedAurobindo Pharm...Selected✓ AUROPHARMA • 524804 | 24.6/100 | ₹1645.00₹1645 | ₹90035.87₹90035.87 | 24.25Average 24.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹7386.50₹7387 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1415.10₹1415 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Biocon LtdBiocon Ltd... BIOCON • 532523 | 30.2/100 | ₹437.95₹438 | ₹70826.50₹70826.50 | 181.85Average 181.8 Average | 1.40%Poor 1.40% Poor | 3.75%Poor 3.75% Poor | 0.45Excellent 0.5 Excellent | -11.84%Poor -11.84% Poor | 18.83%Excellent 18.83% Excellent | 0.12% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 62.3/100 | ₹28900.00₹28900 | ₹58692.31₹58692.31 | 37.82Average 37.8 Average | 34.46%Excellent 34.46% Excellent | 44.89%Excellent 44.89% Excellent | 0.04Excellent 0.0 Excellent | 17.57%Excellent 17.57% Excellent | 9.96%Good 9.96% Good | 1.90% |
JB Chemicals & Pharmaceuticals LtdJB Chemicals & ... JBCHEPHARM • 506943 | 53.9/100 | ₹2408.90₹2409 | ₹40248.14₹40248.14 | 56.02Average 56.0 Average | 18.93%Good 18.93% Good | 25.45%Excellent 25.45% Excellent | 0.00Excellent 0.0 Excellent | 12.37%Good 12.37% Good | 15.22%Excellent 15.22% Excellent | 0.88% |
Wockhardt LtdWockhardt Ltd... WOCKPHARMA • 532300 | 24.6/100 | ₹1953.40₹1953 | ₹30725.07₹30725.07 | 108.16Average 108.2 Average | 6.11%Poor 6.11% Poor | 7.55%Poor 7.55% Poor | 0.45Excellent 0.5 Excellent | -19.25%Poor -19.25% Poor | 4.49%Average 4.49% Average | 0.00% |
ACUTAAS CHEMICALS LIMITEDACUTAAS CHEMICA... ACUTAAS • 543349 | 62.09999999999999/100 | ₹3659.60₹3660 | ₹29036.77₹29036.77 | 81.50Average 81.5 Average | 24.05%Excellent 24.05% Excellent | 31.56%Excellent 31.56% Excellent | 0.02Excellent 0.0 Excellent | 45.77%Excellent 45.77% Excellent | 31.50%Excellent 31.50% Excellent | 0.04% |
Sequent Scientific LtdSequent Scienti... SEQUENT • 512529 | 63.9/100 | ₹188.78₹189 | ₹12241.20₹12241.20 | 61.29Average 61.3 Average | 11.05%Average 11.05% Average | 19.05%Good 19.05% Good | 0.17Excellent 0.2 Excellent | 15.00%Excellent 15.00% Excellent | 20.23%Excellent 20.23% Excellent | 0.00% |
Aarti Pharmalabs LtdAarti Pharmalab... AARTIPHARM • 543748 | 9.1/100 | ₹672.70₹673 | ₹6511.24₹6511.24 | 36.83Average 36.8 Average | 8.59%Poor 8.59% Poor | 10.70%Average 10.70% Average | 0.36Excellent 0.4 Excellent | — — | — — | 0.70% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Divis Laboratories Ltd share price193163.97 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
- Biocon Ltd share price70826.50 Cr
- Abbott India Ltd share price58692.31 Cr
Aurobindo Pharma Limited PE Ratio History
Historical price-to-earnings ratio for AUROPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹59.81 | ₹1183.00 | 19.8x |
| FY 2024 | ₹54.16 | ₹1334.50 | 24.6x |
| FY 2023 | ₹32.90 | ₹1084.00 | 32.9x |
| FY 2022 | ₹45.19 | ₹438.30 | 9.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Aurobindo Pharma Limited Dividend History
Annual cash dividends paid by AUROPHARMA — dividend yield 0.26%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.04 Cr |
| FY 2024 | ₹263.64 Cr |
| FY 2023 | ₹439.53 Cr |
| FY 2022 | ₹263.70 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Aurobindo Pharma Limited Quarterly Performance
Latest quarterly metrics for AUROPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
16.30%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
25.20%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.32%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-8.07%
Compounded annual net profit growth over 5 years
Aurobindo Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AUROPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Aurobindo Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Aurobindo Pharma Limited (AUROPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Aurobindo Pharma Limited
About AUROPHARMA (Aurobindo Pharma Limited)
Aurobindo Pharma Ltd is a global pharmaceutical powerhouse, deeply rooted in the development and manufacturing of a diverse range of healthcare solutions. With a commitment to inno...vation and quality, the company focuses on delivering accessible medicines to patients worldwide. Their broad portfolio encompasses both finished drug formulations and active pharmaceutical ingredients, catering to a variety of therapeutic needs. From cutting-edge manufacturing facilities to a robust research and development infrastructure, Aurobindo Pharma strives to meet the ever-evolving demands of the global healthcare landscape. They operate with a global vision, aiming to expand their reach and impact on patient well-being through strategic partnerships and a dedication to excellence. Aurobindo Pharma specializes in crafting complex generic medications and crucial APIs, ensuring a steady supply of high-quality pharmaceutical products. The company's manufacturing prowess spans various dosage forms, including tablets, capsules, injectables, and inhalers, demonstrating their versatility and commitment to providing comprehensive treatment options. They possess a keen understanding of intricate chemical processes and advanced drug delivery systems. Their API business forms a cornerstone, supplying essential ingredients for numerous medications globally, further solidifying their position within the pharmaceutical ecosystem. This commitment extends to continuous improvement in manufacturing efficiency, sustainability, and adherence to the most stringent regulatory standards. Aurobindo Pharma’s therapeutic focus covers a wide spectrum of medical needs, reflecting their dedication to addressing diverse health challenges. Their offerings include medications targeting cardiovascular ailments, neurological disorders, infectious diseases, and metabolic conditions, among others. By investing in research and development, they strive to create innovative and effective treatments that improve patient outcomes and quality of life. Their dedication to research extends to the development of biosimilars, offering affordable alternatives to complex biologic drugs. This multifaceted approach underscores Aurobindo Pharma's commitment to healthcare accessibility and their mission to serve as a reliable provider of essential medicines to communities around the globe.
Company Details
Key Leadership
Corporate Events
Latest News
AUROPHARMA Share Price: Frequently Asked Questions
What is the current share price of Aurobindo Pharma Limited?
Aurobindo Pharma Limited (AUROPHARMA) trades at ₹1645.00 on NSE and BSE. Market cap ₹90.04K (Cr). Educational data only.
What is the P/E ratio of Aurobindo Pharma Limited?
Aurobindo Pharma Limited has a P/E of 24.25x vs industry average 34.89x.
What is the Bull Run score for Aurobindo Pharma Limited?
Aurobindo Pharma Limited has a Bull Run score of 24.6/100 based on 25+ financial parameters.
Does Aurobindo Pharma Limited pay dividends?
Aurobindo Pharma Limited has a dividend yield of 0.26%. Past dividends don't guarantee future payments.
What is the ROE of Aurobindo Pharma Limited?
Aurobindo Pharma Limited has ROE of 9.94%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Aurobindo Pharma Limited?
Aurobindo Pharma Limited has debt-to-equity of 0.20.
Is Aurobindo Pharma Limited a good investment?
Bull Run gives Aurobindo Pharma Limited a score of 24.6/100. This is not investment advice — consult a SEBI-registered advisor.